Search Results - Barvian, Kevin A

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    α1-Adrenoceptor agonists: The identification of novel α1A Subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines

    α1-Adrenoceptor agonists: The identification of novel α1A Subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines by BISHOP, Michael J, BARVIAN, Kevin A, SAUSSY, David L, SPEAKE, Jason D, BERMAN, Judd, BIGHAM, Eric C, GARRISON, Deanna T, GOBEL, Michael J, HODSON, Stephen J, IRVING, Paul E, LIACOS, James A, NAVAS, Frank III

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines

    alpha(1)-Adrenoceptor agonists: the identification of novel alpha(1A )subtype selective 2'-heteroaryl-2-(phenoxymethyl)imidazolines by Bishop, Michael J, Barvian, Kevin A, Berman, Judd, Bigham, Eric C, Garrison, Deanna T, Gobel, Michael J, Hodson, Stephen J, Irving, Paul E, Liacos, James A, Navas, 3rd, Frank, Saussy, David L, Speake, Jason D

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    α 1-Adrenoceptor Agonists: The Identification of Novel α 1A Subtype Selective 2′-Heteroaryl-2-(phenoxymethyl)imidazolines

    α 1-Adrenoceptor Agonists: The Identification of Novel α 1A Subtype Selective 2′-Heteroaryl-2-(phenoxymethyl)imidazolines by Bishop, Michael J, Barvian, Kevin A, Berman, Judd, Bigham, Eric C, Garrison, Deanna T, Gobel, Michael J, Hodson, Stephen J, Irving, Paul E, Liacos, James A, Navas, III, Frank, Saussy, David L, Speake, Jason D

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

    Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases by Basarab, Gregory S., Kern, Gunther H., McNulty, John, Mueller, John P., Lawrence, Kenneth, Vishwanathan, Karthick, Alm, Richard A., Barvian, Kevin, Doig, Peter, Galullo, Vincent, Gardner, Humphrey, Gowravaram, Madhusudhan, Huband, Michael, Kimzey, Amy, Morningstar, Marshall, Kutschke, Amy, Lahiri, Sushmita D., Perros, Manos, Singh, Renu, Schuck, Virna J. A., Tommasi, Ruben, Walkup, Grant, Newman, Joseph V.

    Published in Scientific reports
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

    Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations... by Conti, Chiara, Campbell, John, Woessner, Rich, Guo, Jian, Timsit, Yoav, Iliou, Maria, Wardwell, Scott, Davis, Alison, Chicklas, Sharon, Hsieh, John, Eno, Meredith, Ahmad, Omar, Fernando, Dilinie, Barvian, Kevin, Kim, Joseph, Kazmirski, Steven, Perola, Emanuele, Dineen, Tom, Brown, Victoria, Guzi, Timothy, Özen, Ayşegül, Stevison, Faith, Utt, Caitlin, Medendorp, Clare, Meissner, Robert, Dorsch, Marion, Hoeflich, Klaus

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    78 - BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations

    78 - BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations by Tavera, Luz, Zhang, Zhuo, Wardwell, Scott, Job, Ebby, McGinn, Katie, Chen, Maxine, Iliou, Maria, Albayya, Faris, Campbell, John, Eno, Meredith, Fernando, Dilinie, Dineen, Tom, Ahmad, Omar, Wilson, Douglas, Barvian, Kevin, Hsieh, John, Medendorp, Clare, Timsit, Yoav, Guo, Jian, Perez, Nisha, Schalm, Stefanie, Woessner, Richard, Conti, Chiara

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations

    BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations by Tavera, Luz, Zhang, Zhuo, Wardwell, Scott, Job, Ebby, McGinn, Katie, Chen, Maxine, Iliou, Maria, Albayya, Faris, Campbell, John, Eno, Meredith, Fernando, Dilinie, Dineen, Tom, Ahmad, Omar, Wilson, Douglas, Barvian, Kevin, Hsieh, John, Medendorp, Clare, Timsit, Yoav, Guo, Jian, Perez, Nisha, Schalm, Stefanie, Woessner, Richard, Conti, Chiara

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Abstract LB565: Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib resistant GIST

    Abstract LB565: Efficacy of a highly potent and selective KIT V654A inhibitor for treatment of imatinib resistant GIST by Grassian, Alexandra R., Kim, Joseph, Ahmad, Omar, Barvian, Kevin, Davis, Alison, Dineen, Tom, Hu, Wei, Job, Ebby, Moine, Ludivine, Newberry, Kate, Roche, Maria, Shorten, Doug, Choi, Yeon Sook, Wolenski, Francis, Bauer, Sebastian, Serrano, Cesar, Trent, Jonathan, George, Suzanne

    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Correction: Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

    Correction: Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoiso... by Basarab, Gregory S., Kern, Gunther H., McNulty, John, Mueller, John P., Lawrence, Kenneth, Vishwanathan, Karthick, Alm, Richard A., Barvian, Kevin, Doig, Peter, Galullo, Vincent, Gardner, Humphrey, Gowravaram, Madhusudhan, Huband, Michael, Kimzey, Amy, Morningstar, Marshall, Kutschke, Amy, Lahiri, Sushmita D., Perros, Manos, Singh, Renu, Schuck, Virna J. A., Tommasi, Ruben, Walkup, Grant, Newman, Joseph V.

    Published in Scientific reports
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Novel benzimidazole-based MCH R1 antagonists

    Novel benzimidazole-based MCH R1 antagonists by Carpenter, Andrew J., Al-Barazanji, Kamal A., Barvian, Kevin K., Bishop, Michael J., Britt, Christy S., Cooper, Joel P., Goetz, Aaron S., Grizzle, Mary K., Hertzog, Donald L., Ignar, Diane M., Morgan, Ronda O., Peckham, Gregory E., Speake, Jason D., Swain, Will R.

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  11. 11
    Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases

    Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases by Basarab, Gregory S, Kern, Gunther H, McNulty, John, Mueller, John P, Lawrence, Kenneth, Vishwanathan, Karthick, Alm, Richard A, Barvian, Kevin, Doig, Peter, Galullo, Vincent, Gardner, Humphrey, Gowravaram, Madhusudhan, Huband, Michael, Kimzey, Amy, Morningstar, Marshall, Kutschke, Amy, Lahiri, Sushmita D, Perros, Manos, Singh, Renu, Schuck, Virna J A, Tommasi, Ruben, Walkup, Grant, Newman, Joseph V

    Published in Scientific reports
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: